Trump Eyes Executive Order on Psychedelic Ibogaine This Week
Administration reportedly preparing executive action on ibogaine treatment protocols, signaling broader federal shift toward psychedelic therapeutics acceptance.
The Trump administration is preparing an executive order focused on the psychedelic compound ibogaine, with reports indicating the directive could be signed within days. The move represents a notable federal acknowledgment of psychedelic medicine's therapeutic potential, particularly for treating addiction and PTSD among veterans and first responders.
Ibogaine, derived from the African iboga plant, has shown promise in clinical settings for opioid addiction treatment but remains federally controlled under Schedule I classification. An executive order could establish research frameworks, treatment protocols, or regulatory pathways that bypass traditional FDA approval timelines for specific patient populations.
The psychedelic sector has attracted substantial investment capital over the past three years, with companies like Compass Pathways and ATAI Life Sciences leading clinical trials for various compounds. Federal recognition of ibogaine's medical applications could accelerate institutional investment in psychedelic research and development, particularly given the compound's unique pharmacological profile compared to psilocybin or MDMA.
This potential executive action aligns with growing bipartisan support for alternative addiction treatments amid the ongoing opioid crisis. Veterans Affairs has expressed interest in psychedelic-assisted therapy trials, while several states have enacted legislation creating legal frameworks for therapeutic psychedelic use. The timing suggests coordination between federal agencies and existing state-level initiatives.
The broader implications extend beyond ibogaine specifically, as federal executive action could establish precedent for other psychedelic compounds currently in clinical development. This regulatory shift would likely benefit biotechnology companies focused on psychedelic medicine while potentially creating new market opportunities for cannabis operators already navigating controlled substance regulations and therapeutic applications.